Skip to content
Inciteful Med

Standard of Care Treatment for Fabry Disease

Last updated:

The standard of care for Fabry disease includes Enzyme Replacement Therapy (ERT) via IV infusion to replace the missing enzyme, or oral chaperone therapy (migalastat) for specific genetic mutations. Starting treatment early is critical to prevent permanent organ damage to the heart and kidneys.

Key Takeaways

  • • Enzyme Replacement Therapy (ERT) provides a synthetic version of the missing alpha-galactosidase A enzyme through regular IV infusions.
  • • Patients with specific amenable genetic mutations may be eligible for migalastat, an oral chaperone therapy taken as a pill every other day.
  • • Starting treatment early is critical to prevent irreversible scarring (fibrosis) in vital organs like the heart and kidneys.
  • • Some patients on ERT may develop anti-drug antibodies, which can make the therapy less effective and require adjustments to the treatment plan.

Managing Fabry disease is a lifelong commitment, but modern medicine has provided powerful tools to slow or even stop the progression of the disease. The goal of all standard treatments is the same: to reduce the buildup of fatty waste (Gb3) in your cells and protect your vital organs [1][2].

Enzyme Replacement Therapy (ERT)

ERT is the traditional standard of care. Since your body cannot make enough of the alpha-galactosidase A (α\alpha-Gal A) enzyme, ERT provides a synthetic version of it directly into your bloodstream [3][4].

  • The Medications: There are three main types of ERT: agalsidase alfa, agalsidase beta, and the more recently approved pegunigalsidase alfa-iwxj [3][5].
  • What to Expect at the Infusion Center: ERT is given as an intravenous (IV) infusion, typically once every two weeks [6][5]. These infusions usually take a few hours. Because there is a risk of Infusion-Associated Reactions (IARs) or allergic responses, they are done in a monitored clinical setting [7]. To prevent these reactions, your team will likely give you “pre-medications” like antihistamines or steroids before the IV starts [7][8]. Over time, if you tolerate the infusions well, many patients are able to transition to home infusions with a visiting nurse [9].
  • How it Works: The synthetic enzyme travels through the blood and is absorbed by your cells, where it goes to work breaking down the accumulated Gb3 “trash” [10][1].

Oral Chaperone Therapy (Migalastat)

If you have a specific type of genetic mutation, you may be eligible for an oral medication called migalastat [11][5].

  • How it Works: Unlike ERT, which replaces the enzyme, migalastat acts like a “staple” or a chaperone. It binds to your body’s own misshapen enzyme, stabilizes it, and helps it get to the right place in the cell to do its job [2][12].
  • Eligibility: This only works for amenable mutations. Your doctor will check your specific GLA mutation against a validated list to see if your enzyme is capable of being “fixed” by this drug [13][14].
  • Administration: This is a pill taken once every other day [12].

The Importance of Early Treatment

The single most important factor in Fabry treatment is timing. Research shows that therapy is much more effective when started before significant damage occurs [15][16].

  • Preventing Fibrosis: Once the heart or kidneys develop fibrosis (permanent scarring), neither ERT nor chaperone therapy can easily reverse it [17][18].
  • Protecting Organs: Early treatment is proven to lower the risk of kidney failure, heart attacks, and strokes [19][1].

Understanding Anti-Drug Antibodies (ADAs)

Some patients, particularly males with the “classic” form of Fabry disease, may develop anti-drug antibodies (ADAs) [7][20].

  • What they are: Your immune system may see the ERT infusion as a “foreign invader” and create antibodies to attack it [21][22].
  • The Impact: These antibodies can “neutralize” the medicine, making it less effective at clearing the Gb3 waste from your cells [7][23].
  • Management: If ADAs develop, your doctor might adjust your dose, increase your pre-meds, or consider switching you to a different type of therapy [7][8].

Choosing a Path

The decision between ERT and migalastat depends on several factors, including your mutation type, your age, and your organ health [11][24]. While both therapies are effective at stabilizing the disease, your medical team will help you decide which fits your biology and your lifestyle best [16][25].

Frequently Asked Questions

What is the difference between ERT and chaperone therapy for Fabry disease?
Enzyme Replacement Therapy (ERT) uses an IV infusion to put synthetic enzyme directly into your blood. Chaperone therapy is an oral pill that binds to your body's own misshapen enzyme, helping it work properly.
Am I eligible to take the migalastat pill instead of ERT?
Eligibility depends on your specific genetic mutation. Your doctor will check your GLA mutation to see if it is 'amenable,' meaning your enzyme is capable of being stabilized by the chaperone drug.
Why is it so important to start Fabry disease treatment early?
Early treatment is crucial because it helps prevent permanent scarring, known as fibrosis, in vital organs like the heart and kidneys. Once this scarring occurs, treatments cannot easily reverse the damage.
What does it mean if I develop anti-drug antibodies?
Sometimes your immune system views the ERT medicine as a foreign invader and creates antibodies against it. These antibodies can neutralize the treatment, making it less effective at clearing waste from your cells.
How often will I need ERT infusions?
Enzyme Replacement Therapy is typically given as an intravenous (IV) infusion once every two weeks. Over time, if you tolerate the infusions well, you may be able to transition to home infusions with a visiting nurse.

Questions for Your Doctor

  • • Is my mutation 'amenable' to migalastat, and if so, what are the pros and cons of an oral pill versus an IV infusion?
  • • Which Enzyme Replacement Therapy (agalsidase alfa, beta, or pegunigalsidase alfa) do you recommend for my specific situation, and why?
  • • If I/my child has a 'classic' mutation, how often will we test for anti-drug antibodies (ADAs)?
  • • We are starting treatment now—do you believe we've caught it early enough to prevent permanent scarring (fibrosis) in the heart or kidneys?
  • • How will we measure if the treatment is working? Will we be tracking Lyso-Gb3 levels or using annual Cardiac MRIs?

Questions for You

  • • How do I feel about the logistics of a biweekly IV infusion versus taking a pill every other day?
  • • Have I noticed any patterns in my symptoms (like pain or fatigue) that I should track to see if they improve after starting treatment?
  • • Am I prepared for the long-term commitment of therapy, knowing that it is most effective when taken consistently?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Enzyme replacement therapy for Anderson-Fabry disease.

    El Dib R, Gomaa H, Carvalho RP, et al.

    The Cochrane database of systematic reviews 2016; (7()):CD006663 doi:10.1002/14651858.CD006663.pub4.

    PMID: 27454104
  2. 2

    [Chaperone molecules: The example of Fabry disease].

    Barbey F, Monney P, Dormond O

    Nephrologie & therapeutique 2021; (17S()):S11-S22 doi:10.1016/j.nephro.2020.02.005.

    PMID: 33910691
  3. 3

    Of the importance of the clinical phenotypes in the interpretation of the studies dealing with Fabry disease.

    Mauhin W, Lidove O, Benveniste O

    Orphanet journal of rare diseases 2019; (14(1)):4 doi:10.1186/s13023-018-0979-z.

    PMID: 30616652
  4. 4

    Safe and Successful Treatment With Agalsidase Beta During Pregnancy in Fabry Disease.

    Senocak Tasci E, Bicik Z

    Iranian journal of kidney diseases 2015; (9(5)):406-8.

    PMID: 26338166
  5. 5

    Progress and Challenges in the Treatment of Fabry Disease.

    Lenders M, Menke ER, Brand E

    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2025; (39(4)):517-535 doi:10.1007/s40259-025-00723-3.

    PMID: 40310476
  6. 6

    Enzyme replacement therapy in a patient of heterozygous Fabry disease: clinical and pathological evaluations by repeat kidney biopsy and a successful pregnancy.

    Iwafuchi Y, Maruyama H, Morioka T, et al.

    CEN case reports 2017; (6(2)):210-214 doi:10.1007/s13730-017-0277-y.

    PMID: 29019163
  7. 7

    Current status of the immunogenicity of enzyme replacement therapy in fabry disease.

    Gómez-Cerezo JF, Fernández-Martín J, Barba-Romero MÁ, et al.

    Orphanet journal of rare diseases 2025; (20(1)):253 doi:10.1186/s13023-025-03705-4.

    PMID: 40420145
  8. 8

    A Fabry Disease Patient Who Developed Hypersensitivity Reaction against Agalsidase Beta following COVID-19 Infection.

    Sonmez O, Ozcan SG, Trabulus S, Seyahi N

    Nephron 2023; (147(3-4)):199-202 doi:10.1159/000526235.

    PMID: 36174537
  9. 9

    Considerations for Home-Based Treatment of Fabry Disease in Poland during the COVID-19 Pandemic and Beyond.

    Nowicki M, Bazan-Socha S, Kłopotowski M, et al.

    International journal of environmental research and public health 2021; (18(16)) doi:10.3390/ijerph18168242.

    PMID: 34443990
  10. 10

    AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction.

    Yasuda M, Huston MW, Pagant S, et al.

    Molecular therapy. Methods & clinical development 2020; (18()):607-619 doi:10.1016/j.omtm.2020.07.002.

    PMID: 32775495
  11. 11

    Fabry Disease Therapy: State-of-the-Art and Current Challenges.

    Azevedo O, Gago MF, Miltenberger-Miltenyi G, et al.

    International journal of molecular sciences 2020; (22(1)) doi:10.3390/ijms22010206.

    PMID: 33379210
  12. 12

    Migalastat: A Review in Fabry Disease.

    McCafferty EH, Scott LJ

    Drugs 2019; (79(5)):543-554 doi:10.1007/s40265-019-01090-4.

    PMID: 30875019
  13. 13

    Inter-assay variability influences migalastat amenability assessments among Fabry disease variants.

    Oommen S, Zhou Y, Meiyappan M, et al.

    Molecular genetics and metabolism 2019; (127(1)):74-85 doi:10.1016/j.ymgme.2019.04.005.

    PMID: 31036492
  14. 14

    The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat.

    Benjamin ER, Della Valle MC, Wu X, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2017; (19(4)):430-438 doi:10.1038/gim.2016.122.

    PMID: 27657681
  15. 15

    Agalsidase alfa long-term effect on left ventricular hypertrophy in Fabry disease.

    Ferrari G, Kisinovsky I, Reisin R, et al.

    Medicina 2024; (84(3)):516-525.

    PMID: 38907966
  16. 16

    Clinical Efficacy and Real-World Effectiveness of Fabry Disease Treatments: A Systematic Literature Review.

    Jovanovic A, Miller-Hodges E, Castriota F, et al.

    Journal of clinical medicine 2025; (14(14)) doi:10.3390/jcm14145131.

    PMID: 40725823
  17. 17

    Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.

    Kim JH, Lee BH, Hyang Cho J, et al.

    Journal of human genetics 2016; (61(11)):923-929 doi:10.1038/jhg.2016.78.

    PMID: 27334365
  18. 18

    Long-Term Effects of Enzyme Replacement Therapy for Anderson-Fabry Disease.

    Tsujiuchi M, Ebato M, Maezawa H, et al.

    International heart journal 2019; (60(1)):208-214 doi:10.1536/ihj.17-688.

    PMID: 30464119
  19. 19

    Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies.

    El Dib R, Gomaa H, Ortiz A, et al.

    PloS one 2017; (12(3)):e0173358 doi:10.1371/journal.pone.0173358.

    PMID: 28296917
  20. 20

    Anti-drug antibody formation in Japanese Fabry patients following enzyme replacement therapy.

    Tsukimura T, Tayama Y, Shiga T, et al.

    Molecular genetics and metabolism reports 2020; (25()):100650 doi:10.1016/j.ymgmr.2020.100650.

    PMID: 33072516
  21. 21

    Assessment of Neutralizing Antibody Activity in Clinical Studies: Use of Surrogate Measurements Instead of Stand-alone Assays.

    Partridge MA, Kamen L, Wu B, et al.

    The AAPS journal 2025; (27(5)):132 doi:10.1208/s12248-025-01118-6.

    PMID: 40804295
  22. 22

    Overcoming Resistance in Anderson-Fabry Disease: Current Therapeutic Challenges and Future Perspectives.

    Carella MC, Forleo C, Caretto P, et al.

    Journal of clinical medicine 2024; (13(23)) doi:10.3390/jcm13237195.

    PMID: 39685654
  23. 23

    Antibodies against recombinant alpha-galactosidase A in Fabry disease: Subclass analysis and impact on response to treatment.

    van der Veen SJ, van Kuilenburg ABP, Hollak CEM, et al.

    Molecular genetics and metabolism 2019; (126(2)):162-168 doi:10.1016/j.ymgme.2018.11.008.

    PMID: 30473480
  24. 24

    Migalastat: First Global Approval.

    Markham A

    Drugs 2016; (76(11)):1147-52 doi:10.1007/s40265-016-0607-y.

    PMID: 27351440
  25. 25

    A Systematic Review on Safety and Efficacy of Migalastat for the treatment of Fabry's Disease.

    Majid H, Verma N, Bhandari S, et al.

    Expert opinion on pharmacotherapy 2024; (25(6)):769-782 doi:10.1080/14656566.2024.2354466.

    PMID: 38753367

This page provides educational information about standard treatments for Fabry disease. Always consult your medical genetics team or doctor to determine the safest and most effective therapy for your specific mutation.

Stay up to date

Get notified when new research about Fabry disease is published.

No spam. Unsubscribe anytime.